Abstract
High-throughput transcriptomics has matured into a very well established and widely utilised research tool over the last two decades. Clinical datasets generated on a range of different platforms continue to be deposited in public repositories provide an ever-growing, valuable resource for reanalysis. Cost and tissue availability normally preclude processing samples across multiple technologies, making it challenging to directly evaluate performance and whether data from different platforms can be reliably compared or integrated.
Original language | English |
---|---|
Journal | BMC Bioinformatics |
Early online date | 28 Jan 2020 |
DOIs | |
Publication status | E-pub ahead of print - 28 Jan 2020 |